Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Waldmann, T. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Waldmann, T. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S101-S106, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

T-cell receptors for cytokines: Targets for immunotherapy of leukemia/lymphoma*

T. A. Waldmann

Metabolism Branch, National Cancer Institute, National Institutes of Health Bethesda, MD, USA

Correspondence to: T. A. Waldmann, MD Metabolism Branch Building 10, Room 4N115 10 Center Drive, MSC 1374 National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1374, USA

Background: Cytokine receptors are exceptionally valuable targets for immunotherapy. For example, the high affinity IL-2 receptor is expressed by abnormal T cells in patients with certain lymphoid malignancies or autoimmune disorders and in individuals rejecting allografts whereas it is not expressed by normal resting cells.

Design: To exploit this difference in receptor expression in normal resting cells and leukemic cells we have introduced different forms of IL-2 receptor directed therapy including an unmodified murine antibody to the {alpha} subunit of the IL-2 receptor (anti-Tac), humanized anti-Tac as well as this antibody armed with truncated Pseudomonas exotoxin or {alpha}- and β-emitting radionuclides (e.g., 211At and 90Y). In particular, unmodified murine anti-Tac was used in the therapy of HTLV-I-associated adult T-cell leukemia (ATL).

Results: Six of nineteen patients treated with this antibody underwent a partial (four) or complete (two) remission. In a subsequent clinical trial involving anti-Tac armed with 90Y over 50% of the patients with ATL treated underwent a partial or complete remission.

Conclusions: New agents under development include humanized antibodies directed toward shared cytokine receptors such as IL-2/15Rβ used by both IL-2 and IL-15 as well as to a shared signal transduction element Jak3 utilized by the T-cell stimulatory cytokines IL-2, IL-4, IL-7, IL-9 and IL-15. Thus our emerging understanding of cytokine receptors and their signaling pathways taken in conjunction with the ability to produce humanized antibodies armed with radionuclides or toxins are providing novel perspectives for the treatment of leukemia and lymphoma.

adult T-cell leukemia, anti-Tac mAb, cytokine, HTLV-I, interleukin-2, interleukin-15

* The US Government's right to retain a non-exclusive, royalty-free licence in and to any copyright is acknowledged.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.